AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cardiol Therapeutics Soars 14.41% on Buy Signal
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Aug 14, 2025 7:02 am ET1min read
Aime SummaryOn August 14, 2025, Cardiol Therapeutics' stock surged by 14.41% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.
Cardiol Therapeutics has recently received a buy signal from a pivot bottom point, which has contributed to its upward momentum. This signal, issued on August 8, 2025, has already resulted in a 10% increase in the stock price, indicating strong investor confidence in the company's prospects.
Analysts have also shown optimism towards
. HC Wainwright initiated coverage on the company, assigning a "buy" rating with a price target of $9.00. This positive outlook reflects the company's potential for growth and its ability to deliver on its promises.Additionally, Cardiol Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. This volatility can be attributed to the company's innovative approach to cardiovascular therapies, which has the potential to disrupt the market and drive significant returns for investors.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Esperion Therapeutics shares plunge 5.14% on Dec. 31 2025 due to regulatory and pipeline shifts
Dec.31 2025
Ses AI (NYSE: SES) plunges 6.28% as investors unwind holiday-driven rally gains amid mixed corporate signals.
Dec.31 2025
Novabay Pharmaceuticals Inc (NBY) Surges 27.57% in Pre-Market on December 31 as Small-Cap Biopharma Gains Lead
Dec.31 2025
Dingdong (Cayman) shares plunge 7.09% amid mixed earnings and strategic shifts
Dec.31 2025
Flushing Financial Corp. Plunges 8.94% Amid Renewed Merger Scrutiny
Dec.31 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet